Non-linear kinetics of 4-methylpyrazole in healthy human subjects

D. Jacobsen, S. K. Barron, C Simon Sebastian, R. Blomstrand, K. E. McMartin

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

In order to evaluate the pharmacokinetic profile of the alcohol dehydrogenase inhibitor 4-methylpyrazole 4-MP, a placebo-controlled, double-blind, single-dose, randomized, sequential, ascending-dose "Phase-I study" was performed in healthy male volunteers at dose levels of 10 (n=4), 20 (n=4), 50 (n=4) and 100 mg·kg-1 (n=3). In the 10 and 20 mg·kg-1 group, the elimination of 4-MP from the plasma followed non-linear kinetics with mean rates of concentration decline of 3.66 and 5.05 μmol·1-1·h-1, respectively. In the two highest dose groups, the elimination also appeared to be non-linear although the patterns were not followed long enough to confirm this, The mean rates of concentration decline at the higher doses were significantly increased, up to 14.9 μmol·l-1·h-1 at 100 mg·kg-1. The average renal clearance of 4-MP was low, 0.016 ml·min-1·kg-1, and only 3% of the administered dose was excreted unchanged in the urine, indicating metabolism as the major route of elimination. Because of the apparently unusual kinetics following single dose treatment, thorough multiple dose studies need to be carried out to determine a safe dosage regimen for 4-MP.

Original languageEnglish (US)
Pages (from-to)599-604
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume37
Issue number6
DOIs
StatePublished - Nov 1 1989
Externally publishedYes

Fingerprint

Healthy Volunteers
Pharmacokinetics
Placebos
Urine
Kidney
4-methylpiperazine-2,6-dione
fomepizole
Therapeutics

Keywords

  • 4-methylpyrazole
  • alcohol dehydrogenase inhibitor
  • healthy volunteers
  • pharmacokinetics
  • saturable kinetics
  • zero order elimination

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Non-linear kinetics of 4-methylpyrazole in healthy human subjects. / Jacobsen, D.; Barron, S. K.; Sebastian, C Simon; Blomstrand, R.; McMartin, K. E.

In: European Journal of Clinical Pharmacology, Vol. 37, No. 6, 01.11.1989, p. 599-604.

Research output: Contribution to journalArticle

Jacobsen, D. ; Barron, S. K. ; Sebastian, C Simon ; Blomstrand, R. ; McMartin, K. E. / Non-linear kinetics of 4-methylpyrazole in healthy human subjects. In: European Journal of Clinical Pharmacology. 1989 ; Vol. 37, No. 6. pp. 599-604.
@article{5af77bb98cc44682844531b86080efb8,
title = "Non-linear kinetics of 4-methylpyrazole in healthy human subjects",
abstract = "In order to evaluate the pharmacokinetic profile of the alcohol dehydrogenase inhibitor 4-methylpyrazole 4-MP, a placebo-controlled, double-blind, single-dose, randomized, sequential, ascending-dose {"}Phase-I study{"} was performed in healthy male volunteers at dose levels of 10 (n=4), 20 (n=4), 50 (n=4) and 100 mg·kg-1 (n=3). In the 10 and 20 mg·kg-1 group, the elimination of 4-MP from the plasma followed non-linear kinetics with mean rates of concentration decline of 3.66 and 5.05 μmol·1-1·h-1, respectively. In the two highest dose groups, the elimination also appeared to be non-linear although the patterns were not followed long enough to confirm this, The mean rates of concentration decline at the higher doses were significantly increased, up to 14.9 μmol·l-1·h-1 at 100 mg·kg-1. The average renal clearance of 4-MP was low, 0.016 ml·min-1·kg-1, and only 3{\%} of the administered dose was excreted unchanged in the urine, indicating metabolism as the major route of elimination. Because of the apparently unusual kinetics following single dose treatment, thorough multiple dose studies need to be carried out to determine a safe dosage regimen for 4-MP.",
keywords = "4-methylpyrazole, alcohol dehydrogenase inhibitor, healthy volunteers, pharmacokinetics, saturable kinetics, zero order elimination",
author = "D. Jacobsen and Barron, {S. K.} and Sebastian, {C Simon} and R. Blomstrand and McMartin, {K. E.}",
year = "1989",
month = "11",
day = "1",
doi = "10.1007/BF00562552",
language = "English (US)",
volume = "37",
pages = "599--604",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Non-linear kinetics of 4-methylpyrazole in healthy human subjects

AU - Jacobsen, D.

AU - Barron, S. K.

AU - Sebastian, C Simon

AU - Blomstrand, R.

AU - McMartin, K. E.

PY - 1989/11/1

Y1 - 1989/11/1

N2 - In order to evaluate the pharmacokinetic profile of the alcohol dehydrogenase inhibitor 4-methylpyrazole 4-MP, a placebo-controlled, double-blind, single-dose, randomized, sequential, ascending-dose "Phase-I study" was performed in healthy male volunteers at dose levels of 10 (n=4), 20 (n=4), 50 (n=4) and 100 mg·kg-1 (n=3). In the 10 and 20 mg·kg-1 group, the elimination of 4-MP from the plasma followed non-linear kinetics with mean rates of concentration decline of 3.66 and 5.05 μmol·1-1·h-1, respectively. In the two highest dose groups, the elimination also appeared to be non-linear although the patterns were not followed long enough to confirm this, The mean rates of concentration decline at the higher doses were significantly increased, up to 14.9 μmol·l-1·h-1 at 100 mg·kg-1. The average renal clearance of 4-MP was low, 0.016 ml·min-1·kg-1, and only 3% of the administered dose was excreted unchanged in the urine, indicating metabolism as the major route of elimination. Because of the apparently unusual kinetics following single dose treatment, thorough multiple dose studies need to be carried out to determine a safe dosage regimen for 4-MP.

AB - In order to evaluate the pharmacokinetic profile of the alcohol dehydrogenase inhibitor 4-methylpyrazole 4-MP, a placebo-controlled, double-blind, single-dose, randomized, sequential, ascending-dose "Phase-I study" was performed in healthy male volunteers at dose levels of 10 (n=4), 20 (n=4), 50 (n=4) and 100 mg·kg-1 (n=3). In the 10 and 20 mg·kg-1 group, the elimination of 4-MP from the plasma followed non-linear kinetics with mean rates of concentration decline of 3.66 and 5.05 μmol·1-1·h-1, respectively. In the two highest dose groups, the elimination also appeared to be non-linear although the patterns were not followed long enough to confirm this, The mean rates of concentration decline at the higher doses were significantly increased, up to 14.9 μmol·l-1·h-1 at 100 mg·kg-1. The average renal clearance of 4-MP was low, 0.016 ml·min-1·kg-1, and only 3% of the administered dose was excreted unchanged in the urine, indicating metabolism as the major route of elimination. Because of the apparently unusual kinetics following single dose treatment, thorough multiple dose studies need to be carried out to determine a safe dosage regimen for 4-MP.

KW - 4-methylpyrazole

KW - alcohol dehydrogenase inhibitor

KW - healthy volunteers

KW - pharmacokinetics

KW - saturable kinetics

KW - zero order elimination

UR - http://www.scopus.com/inward/record.url?scp=0024828952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024828952&partnerID=8YFLogxK

U2 - 10.1007/BF00562552

DO - 10.1007/BF00562552

M3 - Article

VL - 37

SP - 599

EP - 604

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 6

ER -